Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients with Relapsed AL Amyloidosis
ID Number 13-0082Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment.
Bendamustine is currently approved by the Food and Drug Administration (FDA) for treatment of chronic lymphocytic leukemia (CLL) and is under clinical development in the United States for the treatment of non-Hodgkin lymphoma (NHL).
Dexamethasone is a synthetic (man-made) steroid with powerful anti-inflammatory effects. It can also alter your body's immune response.
You may qualify to take part in this research study because you have amyloidosis that has returned after initially responding to treatment (relapsed).
Recruiting Patients: Yes